```html

Polymyositis – A Complete Patient‑Friendly Guide

Overview

Polymyositis (PM) is a rare, chronic inflammatory muscle disease that primarily causes muscle weakness and inflammation in the skeletal muscles closest to the trunk (proximal muscles). It belongs to a group of conditions called the idiopathic inflammatory myopathies, which also includes dermatomyositis and inclusion‑body myositis.

• Who it affects: Adults, usually between ages 30 and 60, but it can occur at any age. Women are affected about twice as often as men.
• Prevalence: Approximately 5–10 cases per 100,000 people in the United States and Europe. The disease is even less common in children (<1 per 100,000).
• Geography: Similar rates are reported worldwide, though higher incidence is noted in northern European populations.

Because polymyositis is an autoimmune disorder, the body’s immune system mistakenly attacks healthy muscle tissue, leading to inflammation, pain, and progressive weakness.

Symptoms

Symptoms develop gradually over weeks to months and often start subtly. The pattern of weakness is typically symmetrical and affects muscles closest to the torso.

Muscular Symptoms

• Proximal muscle weakness: Difficulty climbing stairs, rising from a chair, or lifting objects above shoulder level.
• Fatigue: Persistent tiredness that does not improve with rest.
• Muscle pain (myalgia): Aching or soreness, especially after activity.
• Muscle tenderness: Sensitivity to pressure in affected muscles.
• Difficulty swallowing (dysphagia): Weakness of pharyngeal muscles can cause choking or a feeling of food sticking in the throat.
• Respiratory muscle involvement: Shortness of breath or reduced cough strength, especially when disease is advanced.

Systemic Symptoms

• Low‑grade fever
• Weight loss
• Joint pain (arthralgia) without swelling
• Raynaud’s phenomenon (color changes in fingers/toes in response to cold)
• Skin rash (rare in pure polymyositis, more typical of dermatomyositis)

Causes and Risk Factors

The exact trigger for polymyositis remains unknown, but research points to a combination of genetic susceptibility and environmental factors that provoke an abnormal immune response.

Potential Causes

• Autoimmune dysregulation: T‑cells and auto‑antibodies attack muscle fibers.
• Viral infections: Epstein‑Barr virus, Coxsackievirus, and hepatitis C have been implicated as possible triggers.
• Medications: Certain drugs (e.g., statins, hydralazine, procainamide) can induce a myositis‑like picture, though true polymyositis is distinct.
• Paraneoplastic syndrome: In <5–10% of cases, an underlying cancer (lung, ovarian, colorectal) may precede or accompany the disease.

Risk Factors

• Female sex (2:1 ratio)
• Age 30–60 years
• Family history of autoimmune disease (e.g., lupus, rheumatoid arthritis)
• Exposure to certain viruses or occupational inhalants (silica, organic solvents)
• Concurrent malignancy

Diagnosis

Diagnosing polymyositis requires a step‑wise approach that combines clinical evaluation, laboratory testing, imaging, and sometimes tissue analysis.

Clinical Evaluation

• Comprehensive history focusing on pattern of weakness, associated systemic symptoms, medication use, and family history.
• Physical examination assessing strength (using the Medical Research Council scale), muscle tenderness, and extra‑muscular signs.

Laboratory Tests

• Creatine kinase (CK): Elevated in >90% of patients (often 5–10× upper limit of normal).
• Aspartate/alanine transaminases (AST/ALT): May be modestly raised due to muscle breakdown.
• Autoantibody panels: Anti‑Jo‑1, anti‑Mi‑2, anti‑SRP, and anti‑PL‑7/PL‑12 are associated with polymyositis and may influence prognosis.
• Complete blood count (CBC) and inflammatory markers (ESR, CRP) – frequently elevated but nonspecific.

Imaging

• Magnetic resonance imaging (MRI): Shows muscle edema and inflammation; useful for guiding biopsy sites.
• Ultrasound: Can detect increased echogenicity in inflamed muscles, but less sensitive than MRI.

Electrodiagnostic Studies

• Electromyography (EMG): Reveals characteristic myopathic changes (short duration, low amplitude motor unit potentials).

Muscle Biopsy

Considered the gold standard when the diagnosis is uncertain. Histology typically shows:

• Endomysial inflammation with CD8+ T‑cells
• Muscle fiber necrosis and regeneration
• Absence of perifascicular atrophy (distinguishes it from dermatomyositis)

Diagnostic Criteria

Current practice often follows the 2017 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria, which assign points for:

• Age of onset
• Pattern of weakness
• Serum CK level
• Presence of specific autoantibodies
• EMG/MRI/biopsy findings

A total score ≥7 classifies a patient as having definite polymyositis.

Treatment Options

Therapy aims to suppress the abnormal immune response, improve muscle strength, and prevent complications. Treatment is individualized based on disease severity, comorbidities, and patient preferences.

First‑Line Medications

• Glucocorticoids: Prednisone 0.5–1 mg/kg/day is the initial cornerstone. Rapid symptom improvement is common, but long‑term use is limited by side effects.

Steroid‑Sparing (Immunosuppressive) Agents

• Aza­thioprine: 2–3 mg/kg/day; effective for many patients, especially those needing steroid taper.
• Mycophenolate mofetil: 1–1.5 g twice daily; benefits lung involvement.
• Methotrexate: 15–25 mg weekly; useful when joint symptoms coexist.
• Cyclophosphamide: Reserved for severe, refractory disease or when interstitial lung disease is present.

Biologic Therapies (Refractory Cases)

• Rituximab: Anti‑CD20 monoclonal antibody; shown to improve muscle strength in a subset of patients.
• IVIG (Intravenous Immunoglobulin): Helpful for patients with severe dysphagia or those who cannot tolerate immunosuppressants.
• Emerging agents (e.g., Janus kinase inhibitors) are under clinical investigation.

Physical and Occupational Therapy

• Tailored exercise programs improve muscle strength, endurance, and joint range of motion.
• Assistive devices (canes, braces) may be needed during early recovery.

Lifestyle & Supportive Measures

• Calcium + vitamin D supplementation and weight‑bearing exercise to counteract glucocorticoid‑induced osteoporosis.
• Vaccinations (influenza, pneumococcal, COVID‑19) as immunosuppressed patients are at higher infection risk.
• Regular monitoring for cardiovascular risk (blood pressure, lipid profile) because chronic inflammation raises heart disease risk.

Living with Polymyositis

While there is no cure, most patients achieve meaningful improvement with treatment and can lead active lives.

Daily Management Tips

1. Medication adherence: Take steroids and immunosuppressants exactly as prescribed; never stop abruptly.
2. Schedule regular follow‑ups: Every 3–6 months initially, then annually if stable.
3. Exercise wisely: Low‑impact activities (walking, stationary biking, water aerobics) 3–5 times a week. Warm‑up and stretch before each session.
4. Energy conservation: Break tasks into smaller steps, sit while preparing meals, and use adaptive equipment (e.g., reachers, electric can openers).
5. Nutrition: High‑protein diet (1.2–1.5 g/kg body weight) supports muscle repair; limit excess sodium if on steroids.
6. Skin care: If steroids cause thinning skin, moisturize regularly and avoid harsh soaps.
7. Psychosocial support: Join patient advocacy groups (e.g., Myositis Association) and consider counseling to address depression or anxiety.

Monitoring Parameters

• CK level every 3 months while adjusting therapy.
• Bone mineral density (DEXA) every 1–2 years if on long‑term steroids.
• Pulmonary function tests annually, especially if cough or dyspnea develop.
• Screen for malignancy (age‑appropriate cancer screening, plus chest/abdominal imaging if suspicion arises).

Prevention

Because polymyositis is largely autoimmune and not fully preventable, the focus is on reducing known triggers and minimizing disease exacerbations.

• Avoid known myotoxic drugs: Discuss alternatives with your physician if you need statins or other potentially muscle‑toxic medications.
• Vaccinations: Keep immunizations up to date to prevent infections that might flare the disease.
• Prompt treatment of viral infections: Early antiviral therapy for influenza or COVID‑19 may reduce the risk of triggering a flare.
• Healthy lifestyle: Balanced diet, regular exercise, and smoking cessation lower overall inflammation.

Complications

If inadequately treated, polymyositis can lead to serious health issues:

• Progressive muscle weakness: May result in loss of ambulation or permanent disability.
• Respiratory failure: Weak diaphragm and intercostal muscles can cause chronic respiratory insufficiency.
• Swallowing dysfunction: Increases risk of aspiration pneumonia.
• Calcinosis: Calcium deposits in soft tissue, more common in juvenile cases.
• Interstitial lung disease (ILD): Occurs in 15–30% of patients and can be life‑threatening.
• Cardiac involvement: Myocarditis or conduction abnormalities, though rare, increase mortality.
• Osteoporosis & fractures: Result of chronic steroid use.
• Increased malignancy risk: Especially ovarian, lung, and gastrointestinal cancers; hence vigilant cancer screening is essential.

When to Seek Emergency Care

References

1. Mayo Clinic. “Polymyositis.” Accessed April 2024. https://www.mayoclinic.org
2. NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Polymyositis.” Updated 2023. https://www.niams.nih.gov
3. European League Against Rheumatism (EULAR)/American College of Rheumatology. “Classification Criteria for Idiopathic Inflammatory Myopathies.” *Arthritis Rheumatology* 2017;69(5):1028‑1039.
4. Cleveland Clinic. “Inflammatory Myopathy (Polymyositis & Dermatomyositis).” 2024. https://my.clevelandclinic.org
5. Patel, M. et al. “Management of Polymyositis and Dermatomyositis: Current Consensus.” *Rheumatology International* 2022;42:1235‑1249.
6. World Health Organization. “Guidelines for Cancer Screening in Patients with Autoimmune Diseases.” 2021.
7. Thompson, K. & Howard, J. “Exercise Prescription in Inflammatory Myopathies.” *Physical Therapy* 2023;103(6):p1124‑1135.

```